DOCSLIB.ORG

Phytochemicals Targeting JAK–STAT Pathways in Inflammatory Bowel Disease Models

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Phytochemicals Targeting JAK–STAT Pathways in Inflammatory Bowel Disease Models molecules Review Phytochemicals Targeting JAK–STAT Pathways in Inflammatory Bowel Disease: Insights from Animal Models Sun Young Moon 1,2, Kwang Dong Kim 1,2, Jiyun Yoo 1,2, Jeong-Hyung Lee 3 and Cheol Hwangbo 1,2,* 1 Division of Applied Life Science (BK21), PMBBRC and Research Institute of Life Sciences, Gyeongsang National University, Jinju 52828, Korea; [email protected] (S.Y.M.); [email protected] (K.D.K.); [email protected] (J.Y.) 2 Division of Life Science, College of Natural Sciences, Gyeongsang National University, Jinju 52828, Korea 3 Department of Biochemistry, College of Natural Sciences, Kangwon National University, Chuncheon 24341, Korea; [email protected] * Correspondence: [email protected]; Tel.:+82-55-772-1341 Abstract: Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract that consists of Crohn’s disease (CD) and ulcerative colitis (UC). Cytokines are thought to be key mediators of inflammation-mediated pathological processes of IBD. These cytokines play a crucial role through the Janus kinase (JAK) and signal transducer and activator of transcription (STAT) signaling pathways. Several small molecules inhibiting JAK have been used in clinical trials, and one of them has been approved for IBD treatment. Many anti-inflammatory phytochemicals have been shown to have potential as new drugs for IBD treatment. This review describes the significance of the JAK–STAT pathway as a current therapeutic target for IBD and discusses the recent findings that phytochemicals can ameliorate disease symptoms by affecting the JAK–STAT pathway in vivo in IBD disease models. Thus, we suggest that phytochemicals modulating JAK–STAT pathways are Citation: Moon, S.Y.; Kim, K.D.; potential candidates for developing new therapeutic drugs, alternative medicines, and nutraceutical Yoo, J.; Lee, J.-H.; Hwangbo, C. Phytochemicals Targeting JAK–STAT agents for the treatment of IBD. Pathways in Inflammatory Bowel Disease: Insights from Animal Keywords: inflammatory bowel disease (IBD); janus kinase (JAK); signal transducer and activator of Models. Molecules 2021, 26, 2824. transcription (STAT); phytochemicals https://doi.org/10.3390/ molecules26092824 Academic Editor: Silvie Rimpelová 1. Introduction Plants’ phytochemicals have been used as a source of traditional medicine for millen- Received: 13 April 2021 nia [1]. A large portion of current drugs for disease treatment have originated from plants, Accepted: 7 May 2021 even though new drugs have been developed using synthetic chemistry [2]. Recently, Published: 10 May 2021 the significance of phytochemicals has been emphasized for therapeutic applications with fewer side effects in various inflammation-related diseases, including cancer, diabetes, Publisher’s Note: MDPI stays neutral rheumatoid arthritis, and inflammatory bowel disease (IBD) [3,4]. Phytochemicals are good with regard to jurisdictional claims in sources of new anti-inflammatory drugs that regulate various inflammatory responses published maps and institutional affil- against inflammatory diseases [5]. iations. Inflammatory bowel disease is a typical chronic inflammation-mediated disease of the gastrointestinal (GI) tract [6]. IBD is typically classified into two major forms of chronic and relapsing-remitting inflammation: Crohn’s disease (CD) and ulcerative colitis (UC), which is increasing in incidence and prevalence worldwide [7]. Although both diseases Copyright: © 2021 by the authors. have common clinical features, such as diarrhea and abdominal pain, they differ in various Licensee MDPI, Basel, Switzerland. aspects. Crohn’s disease is characterized by discontinuous inflammation at any location in This article is an open access article the digestive tract, from the mouth to the anus, which can spread into the deeper layers of distributed under the terms and the bowel [8]. On the other hand, ulcerative colitis is a long-standing chronic inflammation conditions of the Creative Commons Attribution (CC BY) license (https:// of the colonic mucosa, which affects certain parts or the entire colon, and is most commonly creativecommons.org/licenses/by/ limited to the mucosal surface [9]. Despite the fact that CD and UC are distinct entities, 4.0/). the precise causes of disease pathogenesis remain largely unknown. Molecules 2021, 26, 2824. https://doi.org/10.3390/molecules26092824 https://www.mdpi.com/journal/molecules Molecules 2021, 26, x FOR PEER REVIEW 2 of 19 Molecules 2021, 26, 2824 2 of 20 most commonly limited to the mucosal surface [9]. Despite the fact that CD and UC are distinct entities, the precise causes of disease pathogenesis remain largely unknown. TheThe significance significance of of treatment treatment and and prevention prevention of of IBD IBD has has been been steadily steadily increasing increasing [10]. [10]. AlthoughAlthough many drugs drugs have have been been developed developed to treat treat IBD, IBD, these these drugs drugs have have adverse adverse effects effects onon the GIGI tracttract [ 11[11].]. In In addition addition to to conventional conventional drugs, drugs, there there have have been been important important advances ad- vancesin IBD in therapy IBD therapy targeting targeting cytokines cytokines that have that been have well been documented well documented to play to a keyplay role a key in roleboth in the both chronic the andchronic relapsing and relapsing phases of phases IBD [12 of]. ForIBD example, [12]. For tumor example, necrosis tumor factor necrosis (TNF) factorinhibitors (TNF) have inhibitors been progressively have been progressively used as therapies used foras therapies IBD. However, for IBD. the However, development the developmentof new drugs of has new been drugs emphasized has been because emphasiz unresponsiveed because patientsunresponsive or patients patients who or have pa- tientslost response who have to anti-TNFlost response therapy to anti-TNF are growing, therapy and are a wide growing, array and of cytokines a wide array besides of cyto- TNF kinesare involved besides inTNF the are pathogenesis involved in ofthe IBD pathogen [13–15].esis Currently, of IBD [13–15]. inhibitors Currently, of JAK andinhibitors STAT ofthat JAK prevent and STAT multiple that prevent pro-inflammatory multiple pro-inflammatory cytokine signaling cytokine pathways signaling in IBD pathways have been in IBDconsidered have been as new considered therapeutic as new approaches therapeuti [16c,17 approaches]. Most cytokines [16,17]. in Mo IBDst cytokines play crucial in rolesIBD playin chronic crucial inflammatory roles in chronic responses inflammatory by activating responses the JAK–STAT by activating pathways the JAK–STAT (Figure1 )[path-18]. waysBinding (Figure of cytokines 1) [18]. toBinding their respective of cytokines transmembrane to their respective receptors transmembrane promotes the activationreceptors promotesof JAK, which the activation allows the of translocation JAK, which allows of STATs the to translocation the nucleus. Eventually,of STATs to they the nucleus. regulate Eventually,the transcription they regulate of specific the target transcription genes [19 ].of Accumulating specific target evidence genes [19]. supports Accumulating the idea thatev- idencetherapeutic supports intervention the idea ofthat the therapeutic JAK–STAT intervention pathway can of efficiently the JAK–STAT modulate pathway the complex can ef- ficientlyinflammation modulate driven the bycomplex various inflammation cytokines in driven IBD [20 by]. various In particular, cytokines tofacitinib, in IBD [20]. a JAK In particular,inhibitor, hastofacitinib, already a been JAK approvedinhibitor, andhas already is clinically been used approved for UC and patients, is clinically and manyused forother UC inhibitors patients, and are nowmany being other studied inhibitors in preclinicalare now being and studied clinical in trial preclinical phases [and17]. clin- JAK icalinhibitors trial phases are small [17]. moleculesJAK inhibitors that blockare sm JAKall molecules activity, whichthat block transduces JAK activity, signals which from transducescytokine-receptors signals from to STAT cytokine-receptors [21]. In addition, to direct STAT inhibitors [21]. In addition, of STAT direct have beeninhibitors studied of STATin preclinical have been models studied of IBD, in preclinical even though models no clinical of IBD, trials even have though been no undertaken clinical trials for have IBD beenpatients undertaken [22]. Compared for IBD topatients conventional [22]. Comp treatments,ared to targetingconventional the JAK–STAT treatments, pathway targeting is theconsidered JAK–STAT a new pathway therapeutic is considered strategy a for new IBD th patientserapeutic [20 strategy]. for IBD patients [20]. Figure 1. JAK–STAT signaling pathway activated in response to cytokines. Binding of cytokines to Figure 1. JAK–STAT signaling pathway activated in response to cytokines. Binding of cytokines to their cognate receptors triggers the phosphorylation of JAK and its receptors. After that, recruited their cognate receptors triggers the phosphorylation of JAK and its receptors. After that, recruited STAT is phosphorylated and translocated as homo- or heterodimers to the nucleus, where they upregulateSTAT is phosphorylated the transcription and of translocatedcytokine-responsive as homo- genes. or heterodimers to the nucleus, where they upregulate the transcription of cytokine-responsive genes. Anti-inflammatory phytochemicals are known to have anti-IBD activity by modulat- Anti-inflammatory phytochemicals
Load more

Recommended publications
  • Peumus Boldus Mol.) Rescate De Un Patrimonio Forestal Chileno Manejo Sustentable Y Valorización De Sus Productos
    Boldo(Peumus boldus Mol.) Rescate de un Patrimonio Forestal Chileno Manejo Sustentable y Valorización de sus Productos EDITORES Susana Benedetti Ruiz1 Santiago Barros Asenjo2 1 Ingeniera Forestal. Investigadora Sede Metropolitana INFOR. Jefa Proyecto Innovación Silvícola e Industrial del Boldo en la Zona Central de Chile. [email protected] 2 Ingeniero Forestal. Relaciones Internacionales y Transferencia Tecnológica INFOR [email protected] Boldo (Peumus boldus Mol.) - Rescate de un patrimonio forestal chileno. Prólogo MANEJO SUSTENTABLE Y VALORIZACIÓN DE SUS PRODUCTOS PRÓLOGO El boldo (Peumus boldus Mol.) es una especie nativa y endémica de Chile presente en formaciones naturales de amplia distribución en la zona central y sur del país, entre las Regiones de Coquimbo y Los Lagos. El uso de su madera, sus hojas y sus frutos es de larga data; los pueblos originarios antes de la llegada de los españoles ya usaban sus hojas para infusiones con fines digestivos y medicinales lo que sigue siendo una arraigada costumbre nacional. Su valor medicinal radica en principios activos contenidos tanto en sus hojas como en su corteza. El principal de ellos es el alcaloide conocido como boldina, producto que ya en el siglo XIX despertaba el interés en otros países, como Francia, donde en 1872 ya se realizaban investigaciones sobre sus propiedades. Desde principios del siglo XX las hojas de boldo han trascendido el mercado nacional y se han ex- portado a distintos países con la consecuente presión sobre el recurso, el cual se ha visto reducido en superficie y degradado en los bosques existentes debido a prácticas extractivas que no aseguran su sustentabilidad.
    [Show full text]
  • Ruxolitinib for Symptom Control in Patients with Chronic Lymphocytic Leukaemia: a Single- Group, Phase 2 Trial
    UC Irvine UC Irvine Previously Published Works Title Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single- group, phase 2 trial. Permalink https://escholarship.org/uc/item/1180x27h Journal The Lancet. Haematology, 4(2) ISSN 2352-3026 Authors Jain, Preetesh Keating, Michael Renner, Sarah et al. Publication Date 2017-02-01 DOI 10.1016/s2352-3026(16)30194-6 Peer reviewed eScholarship.org Powered by the California Digital Library University of California HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Lancet Haematol Manuscript Author . Author Manuscript Author manuscript; available in PMC 2018 February 01. Published in final edited form as: Lancet Haematol. 2017 February ; 4(2): e67–e74. doi:10.1016/S2352-3026(16)30194-6. Ruxolitinib for symptom control in patients with Chronic Lymphocytic leukemia: A Phase II Trial Preetesh Jain, M.D.,PhD1, Michael Keating, M.D.1,*, Sarah Renner, RN1, Charles Cleeland, PhD2,*, Huang Xuelin, PhD3,*, Graciela Nogueras Gonzalez, M.P.H3, David Harris, PhD1, Ping Li, PhD1, Zhiming Liu, PhD1, Ivo Veletic, PhD1, Uri Rozovski, M.D.1, Nitin Jain, M.D.1, Phillip Thompson, M.D.1, Prithviraj Bose, M.D.1, Courtney DiNardo, M.D.1, Alessandra Ferrajoli, M.D.1,*, Susan O’Brien, M.D.1,*, Jan Burger, M.D.1, William Wierda, M.D.1,*, Srdan Verstovsek, M.D.1,*, Hagop Kantarjian, M.D.1,*, and Zeev Estrov, M.D.1,* 1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas 2Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, Texas 3Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas Summary Background—Disease-related symptoms impair the quality of life of countless patients with chronic lymphocytic leukemia (CLL) who do not require systemic therapy.
    [Show full text]
  • JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors
    Drugs https://doi.org/10.1007/s40265-020-01261-8 CURRENT OPINION JAK Inhibitors for Treatment of Psoriasis: Focus on Selective TYK2 Inhibitors Miguel Nogueira1 · Luis Puig2 · Tiago Torres1,3 © Springer Nature Switzerland AG 2020 Abstract Despite advances in the treatment of psoriasis, there is an unmet need for efective and safe oral treatments. The Janus Kinase– Signal Transducer and Activator of Transcription (JAK–STAT) pathway plays a signifcant role in intracellular signalling of cytokines of numerous cellular processes, important in both normal and pathological states of immune-mediated infamma- tory diseases. Particularly in psoriasis, where the interleukin (IL)-23/IL-17 axis is currently considered the crucial pathogenic pathway, blocking the JAK–STAT pathway with small molecules would be expected to be clinically efective. However, relative non-specifcity and low therapeutic index of the available JAK inhibitors have delayed their integration into the therapeutic armamentarium of psoriasis. Current research appears to be focused on Tyrosine kinase 2 (TYK2), the frst described member of the JAK family. Data from the Phase II trial of BMS-986165—a selective TYK2 inhibitor—in psoriasis have been published and clinical results are encouraging, with a large Phase III programme ongoing. Further, the selective TYK2 inhibitor PF-06826647 is being tested in moderate-to-severe psoriasis in a Phase II clinical trial. Brepocitinib, a potent TYK2/JAK1 inhibitor, is also being evaluated, as both oral and topical treatment. Results of studies with TYK2 inhibitors will be important in assessing the clinical efcacy and safety of these drugs and their place in the therapeutic armamentarium of psoriasis.
    [Show full text]
  • Understanding and Managing the Transition Using Essential Oils Vs
    MENOPAUSE: UNDERSTANDING AND MANAGING THE TRANSITION USING ESSENTIAL OILS VS. TRADITIONAL ALLOPATHIC MEDICINE by Melissa A. Clanton A thesis submitted in partial fulfillment of the requirements for the Diploma of Aromatherapy 401 Australasian College of Health Sciences Instructors: Dorene Petersen, Erica Petersen, E. Joy Bowles, Marcangelo Puccio, Janet Bennion, Judika Illes, and Julie Gatti TABLE OF CONTENTS List of Tables and Figures............................................................................ iv Acknowledgments........................................................................................ v Introduction.................................................................................................. 1 Chapter 1 – Female Reproduction 1a – The Female Reproductive System............................................. 4 1b - The Female Hormones.............................................................. 9 1c – The Menstrual Cycle and Pregnancy....................................... 12 Chapter 2 – Physiology of Menopause 2a – What is Menopause? .............................................................. 16 2b - Physiological Changes of Menopause ..................................... 20 2c – Symptoms of Menopause ....................................................... 23 Chapter 3 – Allopathic Approaches To Menopausal Symptoms 3a –Diagnosis and Common Medical Treatments........................... 27 3b – Side Effects and Risks of Hormone Replacement Therapy ...... 32 3c – Retail Cost of Common Hormone Replacement
    [Show full text]
  • JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: a Focus on the Present and an Outlook on the Future
    biomolecules Review JAK-Inhibitors for the Treatment of Rheumatoid Arthritis: A Focus on the Present and an Outlook on the Future 1, 2, , 3 1,4 Jacopo Angelini y , Rossella Talotta * y , Rossana Roncato , Giulia Fornasier , Giorgia Barbiero 1, Lisa Dal Cin 1, Serena Brancati 1 and Francesco Scaglione 5 1 Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan, 20133 Milan, Italy; [email protected] (J.A.); [email protected] (G.F.); [email protected] (G.B.); [email protected] (L.D.C.); [email protected] (S.B.) 2 Department of Clinical and Experimental Medicine, Rheumatology Unit, AOU “Gaetano Martino”, University of Messina, 98100 Messina, Italy 3 Experimental and Clinical Pharmacology Unit, Centro di Riferimento Oncologico di Aviano (CRO), Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Pordenone, 33081 Aviano, Italy; [email protected] 4 Pharmacy Unit, IRCCS-Burlo Garofolo di Trieste, 34137 Trieste, Italy 5 Head of Clinical Pharmacology and Toxicology Unit, Grande Ospedale Metropolitano Niguarda, Department of Oncology and Onco-Hematology, Director of Postgraduate School of Clinical Pharmacology and Toxicology, University of Milan, 20162 Milan, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-090-2111; Fax: +39-090-293-5162 Co-first authors. y Received: 16 May 2020; Accepted: 1 July 2020; Published: 5 July 2020 Abstract: Janus kinase inhibitors (JAKi) belong to a new class of oral targeted disease-modifying drugs which have recently revolutionized the therapeutic panorama of rheumatoid arthritis (RA) and other immune-mediated diseases, placing alongside or even replacing conventional and biological drugs.
    [Show full text]
  • Clinical Efficacy of New JAK Inhibitors Under Development. Just More of the Same?
    RHEUMATOLOGY Rheumatology 2019;58:i27i33 doi:10.1093/rheumatology/key256 Clinical efficacy of new JAK inhibitors under development. Just more of the same? Rene Westhovens1 Abstract Janus kinase inhibition is promising in the treatment of RA, with already two oral drugs marketed. New compounds are under investigation that are more selective for Janus kinase 1 or Janus kinase 3. Phase II results for filgotinib, upadacitinib, peficitinib and decernotinib are reviewed showing almost consistently a fast dose-dependent clinical improvement similar to already approved drugs tofacitinib and baricitinib. I will reflect on the most frequently reported dose-dependent adverse events and laboratory changes. Some are similar for all drugs of this class, some are more specific for a certain drug, but all may influence future treatment effectiveness in daily practice. This implies the need for a critical evaluation of phase III trials, and eventually trials specifically powered for conclusions on the safety profile and registries once these drugs become marketed. These innovative drugs also need head-to-head trials versus biologics or in-class as well as specific strategy studies to determine their optimal future use. Key words: Janus kinase inhibitor, RA, filgotinib, upadacitinib, peficitinib, decernotinib Rheumatology key messages . Efficacy but also some adverse events of most new Janus kinase inhibitors are dose dependent. Target selectivity of new Janus kinase inhibitors is an interplay between selectivity, dosing, drugdrug interaction, pharmacokinetics and pharmacodynamics. These new Janus kinase inhibitors might alter treatment paradigms by a rapid dose-dependent action, eventually also in monotherapy. Introduction regarding functionality, quality of life and even aspects of participation in daily life.
    [Show full text]
  • Clinical Review Report for Upadacitinib (Rinvoq) 2
    CADTH COMMON DRUG REVIEW Clinical Review Report Upadacitinib (Rinvoq) (AbbVie) Indication: For the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. Service Line: CADTH Common Drug Review Version: Final (with redactions) Publication Date: March 2020 Report Length: 116 Pages Disclaimer: The information in this document is intended to help Canadian health care decision-makers, health care professionprofessionals,als, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patientspatients and others may access this documendocument,t, the document is made available for informational purposes only and no rrepresentationsepresentations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be usedused as a substitute for professional medical advice or as a substitusubstitutete for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processesprocesses,, or servicservices.es. While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-datedate as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any thithirdrd-party materials used in preparing this document.
    [Show full text]
  • Switching Between Janus Kinase Inhibitor Upadacitinib and Adalimumab Following Insufficient Response: Efficacy and Safety In
    Ann Rheum Dis: first published as 10.1136/annrheumdis-2020-218412 on 4 November 2020. Downloaded from Rheumatoid arthritis CLINICAL SCIENCE Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis Roy M Fleischmann ,1 Ricardo Blanco ,2 Stephen Hall,3 Glen T D Thomson,4 Filip E Van den Bosch,5,6 Cristiano Zerbini,7 Louis Bessette,8,9 Jeffrey Enejosa,10 Yihan Li,10 Yanna Song,10 Ryan DeMasi,10 In- Ho Song10 Handling editor Josef S ABSTRACT Key messages Smolen Objectives To evaluate efficacy and safety of immediate switch from upadacitinib to adalimumab, or ► Additional material is What is already known about this subject? published online only. To view, vice versa, in patients with rheumatoid arthritis with non- ► In patients with rheumatoid arthritis, a treat- please visit the journal online response or incomplete- response to the initial therapy. to- target strategy is recommended, in which (http:// dx. doi. org/ 10. 1136/ Methods SELECT-COMP ARE randomised patients to therapy is optimised every 3–6 months until annrheumdis- 2020- 218412). upadacitinib 15 mg once daily (n=651), placebo (n=651) remission, or low disease activity, is achieved. or adalimumab 40 mg every other week (n=327). A For numbered affiliations see Recent treatment recommendations suggest the treat-to- target study design was implemented, with end of article. addition of a biological or targeted- synthetic blinded rescue occurring prior to week 26 for patients disease- modifying antirheumatic drug in Correspondence to who did not achieve at least 20% improvement in both patients who do not achieve treatment goals, Dr Roy M Fleischmann, The tender and swollen joint counts (’non-responders’) and and switches between mechanisms of action University of Texas at week 26 based on Clinical Disease Activity Index Southwestern Medical Center, occur commonly in clinical practice.
    [Show full text]
  • Note: the Letters 'F' and 'T' Following the Locators Refers to Figures and Tables
    Index Note: The letters ‘f’ and ‘t’ following the locators refers to figures and tables cited in the text. A Acyl-lipid desaturas, 455 AA, see Arachidonic acid (AA) Adenophostin A, 71, 72t aa, see Amino acid (aa) Adenosine 5-diphosphoribose, 65, 789 AACOCF3, see Arachidonyl trifluoromethyl Adlea, 651 ketone (AACOCF3) ADP, 4t, 10, 155, 597, 598f, 599, 602, 669, α1A-adrenoceptor antagonist prazosin, 711t, 814–815, 890 553 ADPKD, see Autosomal dominant polycystic aa 723–928 fragment, 19 kidney disease (ADPKD) aa 839–873 fragment, 17, 19 ADPKD-causing mutations Aβ, see Amyloid β-peptide (Aβ) PKD1 ABC protein, see ATP-binding cassette protein L4224P, 17 (ABC transporter) R4227X, 17 Abeele, F. V., 715 TRPP2 Abbott Laboratories, 645 E837X, 17 ACA, see N-(p-amylcinnamoyl)anthranilic R742X, 17 acid (ACA) R807X, 17 Acetaldehyde, 68t, 69 R872X, 17 Acetic acid-induced nociceptive response, ADPR, see ADP-ribose (ADPR) 50 ADP-ribose (ADPR), 99, 112–113, 113f, Acetylcholine-secreting sympathetic neuron, 380–382, 464, 534–536, 535f, 179 537f, 538, 711t, 712–713, Acetylsalicylic acid, 49t, 55 717, 770, 784, 789, 816–820, Acrolein, 67t, 69, 867, 971–972 885 Acrosome reaction, 125, 130, 301, 325, β-Adrenergic agonists, 740 578, 881–882, 885, 888–889, α2 Adrenoreceptor, 49t, 55, 188 891–895 Adult polycystic kidney disease (ADPKD), Actinopterigy, 223 1023 Activation gate, 485–486 Aframomum daniellii (aframodial), 46t, 52 Leu681, amino acid residue, 485–486 Aframomum melegueta (Melegueta pepper), Tyr671, ion pathway, 486 45t, 51, 70 Acute myeloid leukaemia and myelodysplastic Agelenopsis aperta (American funnel web syndrome (AML/MDS), 949 spider), 48t, 54 Acylated phloroglucinol hyperforin, 71 Agonist-dependent vasorelaxation, 378 Acylation, 96 Ahern, G.
    [Show full text]
  • Periodic Table of Herbs 'N Spices
    Periodic Table of Herbs 'N Spices 11HH 1 H 2 HeHe Element Proton Element Symbol Number Chaste Tree Chile (Vitex agnus-castus) (Capsicum frutescens et al.) Hemptree, Agnus Cayenne pepper, Chili castus, Abraham's balm 118Uuo Red pepper 33LiLi 44 Be 5 B B 66 C 7 N 7N 88O O 99 F 1010 Ne Ne Picture Bear’s Garlic Boldo leaves Ceylon Cinnamon Oregano Lime (Allium ursinum) (Peumus boldus) (Cinnamomum zeylanicum) Nutmeg Origanum vulgare Fenugreek Lemon (Citrus aurantifolia) Ramson, Wild garlic Boldina, Baldina Sri Lanka cinnamon (Myristica fragrans) Oregan, Wild marjoram (Trigonella foenum-graecum) (Citrus limon) 11 Na Na 1212 Mg Mg 1313 Al Al 1414 Si Si 1515 P P 16 S S 1717 Cl Cl 1818 Ar Ar Common Name Scientific Name Nasturtium Alternate name(s) Allspice Sichuan Pepper et al. Grains of Paradise (Tropaeolum majus) (Pimenta dioica) (Zanthoxylum spp.) Perilla (Aframomum melegueta) Common nasturtium, Jamaica pepper, Myrtle Anise pepper, Chinese (Perilla frutescens) Guinea grains, Garden nasturtium, Mugwort pepper, Pimento, pepper, Japanese Beefsteak plant, Chinese Savory Cloves Melegueta pepper, Indian cress, Nasturtium (Artemisia vulgaris) Newspice pepper, et al. Basil, Wild sesame (Satureja hortensis) (Syzygium aromaticum) Alligator pepper 1919 K K 20 Ca Ca 2121 Sc Sc 2222 Ti Ti 23 V V 24 Cr Cr 2525 Mn Mn 2626 Fe Fe 2727 Co Co 2828 Ni Ni 29 Cu Cu 3030 Zn Zn 31 Ga Ga 3232 Ge Ge 3333As As 34 Se Se 3535 Br Br 36 Kr Kr Cassia Paprika Caraway (Cinnamomum cassia) Asafetida Coriander Nigella Cumin Gale Borage Kaffir Lime (Capsicum annuum) (Carum carvi)
    [Show full text]
  • Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis
    REVIEW published: 09 July 2021 doi: 10.3389/fimmu.2021.686155 Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis † † Jie Huang 1 , Xuekun Fu 1 , Xinxin Chen 1, Zheng Li 1, Yuhong Huang 1 and Chao Liang 1,2* 1 Department of Biology, Southern University of Science and Technology, Shenzhen, China, 2 Institute of Integrated Bioinfomedicine and Translational Science (IBTS), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China Rheumatoid arthritis (RA) is a systemic poly-articular chronic autoimmune joint disease that mainly damages the hands and feet, which affects 0.5% to 1.0% of the population worldwide. With the sustained development of disease-modifying antirheumatic drugs (DMARDs), significant success has been achieved for preventing and relieving disease activity in RA patients. Unfortunately, some patients still show limited response to DMARDs, which puts forward new requirements for special targets and novel therapies. Understanding the pathogenetic roles of the various molecules in RA could facilitate discovery of potential therapeutic targets and approaches. In this review, both Edited by: existing and emerging targets, including the proteins, small molecular metabolites, and Trine N. Jorgensen, epigenetic regulators related to RA, are discussed, with a focus on the mechanisms that Case Western Reserve University, result in inflammation and the development of new drugs for blocking the various United States modulators in RA. Reviewed by: Åsa Andersson, Keywords: rheumatoid arthritis, targets, proteins, small molecular metabolites, epigenetic regulators Halmstad University, Sweden Abdurrahman Tufan, Gazi University, Turkey *Correspondence: INTRODUCTION Chao Liang [email protected] Rheumatoid arthritis (RA) is classified as a systemic poly-articular chronic autoimmune joint † disease that primarily affects hands and feet.
    [Show full text]
  • Herbs, Spices and Essential Oils
    Printed in Austria V.05-91153—March 2006—300 Herbs, spices and essential oils Post-harvest operations in developing countries UNITED NATIONS INDUSTRIAL DEVELOPMENT ORGANIZATION Vienna International Centre, P.O. Box 300, 1400 Vienna, Austria Telephone: (+43-1) 26026-0, Fax: (+43-1) 26926-69 UNITED NATIONS FOOD AND AGRICULTURE E-mail: [email protected], Internet: http://www.unido.org INDUSTRIAL DEVELOPMENT ORGANIZATION OF THE ORGANIZATION UNITED NATIONS © UNIDO and FAO 2005 — First published 2005 All rights reserved. Reproduction and dissemination of material in this information product for educational or other non-commercial purposes are authorized without any prior written permission from the copyright holders provided the source is fully acknowledged. Reproduction of material in this information product for resale or other commercial purposes is prohibited without written permission of the copyright holders. Applications for such permission should be addressed to: - the Director, Agro-Industries and Sectoral Support Branch, UNIDO, Vienna International Centre, P.O. Box 300, 1400 Vienna, Austria or by e-mail to [email protected] - the Chief, Publishing Management Service, Information Division, FAO, Viale delle Terme di Caracalla, 00100 Rome, Italy or by e-mail to [email protected] The designations employed and the presentation of material in this information product do not imply the expression of any opinion whatsoever on the part of the United Nations Industrial Development Organization or of the Food and Agriculture Organization of the United Nations concerning the legal or development status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
    [Show full text]